

UPADACITINIB prolonged-release tablets (RINVOQ® ▼) for treating moderate rheumatoid arthritis

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ® ▼) for treating moderate rheumatoid arthritis.

GREY

Upadacitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.^[1]

Please refer to the separate [Pan Mersey APC prescribing statement](#) for the use of upadacitinib in **severe** rheumatoid arthritis.

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, clinicians should continue to follow national guidance, local pathways and local formulary choices for the treatment of rheumatoid arthritis.

- > NICE guideline [NG100]: [Rheumatoid arthritis in adults: management](#) (last updated 12 October 2020)
- > NICE Pathway: [Rheumatoid arthritis](#) (last updated: 22 December 2020)
- > Pan Mersey APC Pathway: [Rheumatoid arthritis high cost drugs pathway](#) (last updated 23 September 2020)
- > Pan Mersey APC Formulary Chapter 10.01: [Drugs used in rheumatic diseases and gout](#)

References

1. AbbVie Ltd. Summary of Product Characteristics; [RINVOQ 15 mg prolonged-release tablets](#), 13 November 2020. Accessed online 29 January 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.